Extended Data Figure 3: Targeting CHD1 has minimal impact on tumour growth of PTEN-intact prostate cancer.
From: Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
a, Immunoblots of lysates and colony-formation assays generated from CHD1-knockdown and control 22Rv1 cells, followed by measurement of subcutaneous tumour growth in vivo (control group n = 8; shCHD1 group n = 7). b, Immunoblots of lysates and colony formation assays generated from CHD1-knockdown and control RWPE-2 cells. c, Immunoblots of lysates and colony formation assays generated from CHD1-knockdown wild-type or PTEN-knockout DU145 cells. d, Weights of subcutaneous tumours derived from CHD1-knockdown DU145 cells (n = 5 for the PTEN-knockout shCHD1 group; other group n = 6). e, CHD1 mRNA levels were detected by qPCR in PC-3 cells overexpressing PTEN. f, Immunoblot time courses of CHD1 protein in control PC-3 (GFP) and PTEN-overexpressing (HA–PTEN) cells treated with 50 μg ml−1 cycloheximide (CHX). C-Myc was used as the positive control, LDH-A as the negative control. g, Immunoblot time courses of CHD1 protein in LNCaP and 22Rv1 cells treated with cycloheximide. h, Immunoblot of CHD1 protein in PTEN-intact and -deficient cell lines. Error bars in a and d indicate s.d. P values were determined by two-tailed t-test. N.S., not significant.
